Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model


Sarepta Therapeutics



) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.6%. By the end of trading, Sarepta Therapeutics fell $2.26 (-7.3%) to $28.75 on average volume. Throughout the day, 2.4 million shares of Sarepta Therapeutics exchanged hands as compared to its average daily volume of 2.7 million shares. The stock ranged in price between $28.65-$31.87 after having opened the day at $31.52 as compared to the previous trading day's close of $31.01. Other companies within the Drugs industry that declined today were:

Neptune Technologies & Bioressources



), down 24.5%,

Aoxing Pharmaceutical Company



), down 19.2%,




), down 9.3%, and

Rosetta Genomics



), down 7%.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of serious and life-threatening rare and infectious diseases. Sarepta Therapeutics has a market cap of $747 million and is part of the health care sector. The company has a P/E ratio of -3.7, below the S&P 500 P/E ratio of 17.7. Shares are up 4062.4% year to date as of the close of trading on Monday. Currently there are four analysts that rate Sarepta Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Sarepta Therapeutics as a


. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and feeble growth in its earnings per share.

On the positive front,

ACADIA Pharmaceuticals



), up 136.1%,

Peregrine Pharmaceuticals



), up 26.8%,




), up 19.4%, and




), up 14%, were all gainers within the drugs industry with

Watson Pharmaceuticals



) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!